Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization

Exclusion Criteria

• •Left main stem lesion: Left main coronary artery stenosis ≥50% by coronary angiographic visual estimation.
• •History of coronary artery bypass graft surgery (CABG).
• •Unstable clinical condition (hemodynamic or electrical instability).
• •Severe coronary artery calcification or tortuosity interfering with IVUS, NIRS, or evaluation.
• •Uncontrolled cardiac arrhythmia (recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response) not controlled by medication within 3 months prior to screening.
• •Active liver disease or liver dysfunction.
• •Severe renal dysfunction (eGFR \<30 mL/min/1.73m²)
• •Known allergy to contrast media, heparin, aspirin, ticagrelor, or prasugrel.
• •Active infection or major hematologic, metabolic, or endocrine dysfunction as determined by the investigator.
• •Planned surgery within 12 months.
• •Currently enrolled in another investigational device or drug study.
• •Estimated life expectancy of less than 2 years.
• •Women of childbearing potential (under 50 years of age) who:
• •* Had their last menstrual period within the last 12 months.
• •* Have not had tubal ligation, oophorectomy, or hysterectomy.